valdecoxib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
selective cyclo-oxygenase inhibitors 2799 181695-72-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • valdecoxib
  • valecoxib
a COX-2 inhibitor
  • Molecular weight: 314.36
  • Formula: C16H14N2O3S
  • CLOGP: 1.83
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 86.19
  • ALOGS: -3.96
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.12 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.40 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.621 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.498 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 81.658 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 4.560 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 4.640 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 12.580 % High 1
herg hERG pIC50 4.697 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.576 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.707 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 2.750 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK14,MAPK7,MAPK9,MAPKAPK2,MARK4,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK33,TEK,TTK 38
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.296 High 1
mh-clint Mouse hepatocyte intrinsic clearance 8.241 High 1
mppb Mouse plasma protein binding (% unbound) 4.670 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 7.534 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 11.090 % High 1
rh-clint Rat hepatocyte intrinsic clearance 6.180 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 43.640 % High 1
rppb Rat plasma protein binding (% unbound) 4.500 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 35.727 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 16, 2001 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 170.78 66.73 60 226 463549 90164612

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 189.26 55.96 51 88 454039 110135121

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AH03 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Coxibs
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D052246 Cyclooxygenase 2 Inhibitors
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:35493 antipyretic
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:50629 cyclooxygenase 2 inhibitor
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

M01AH Coxibs 6 drugs
celecoxibetoricoxiblumiracoxibparecoxibpolmacoxibrofecoxib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute postoperative pain indication 107401000119105
Rheumatoid arthritis off-label use 69896004 DOID:7148
Dysmenorrhea off-label use 266599000
Osteoarthritis off-label use 396275006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.85 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 8.30 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 4.57 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.54 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.74 PDSP
Carbonic anhydrase 2 Enzyme IC50 7.37 WOMBAT-PK
Carbonic anhydrase 1 Enzyme Ki 4.27 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.87 CHEMBL
Carbonic anhydrase 9 Enzyme IC50 7.57 WOMBAT-PK
Carbonic anhydrase 12 Enzyme Ki 7.89 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.04 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.06 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.41 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 4.11 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.24 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 6.97 CHEMBL
Cytochrome c oxidase subunit 2 Enzyme IC50 5.96 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 6.37 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 6.37 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.47 CHEMBL
Carbonic anhydrase Enzyme Ki 6.89 CHEMBL
Carbonic anhydrase Enzyme Ki 4.21 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.18 CHEMBL
Carbonic anhydrase Enzyme Ki 6.18 CHEMBL
Carbonic anhydrase Enzyme Ki 7.37 CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme Ki 5.11 CHEMBL
Carbonic anhydrase Enzyme Ki 7.01 CHEMBL
Alpha carbonic anhydrase Enzyme Ki 7.54 CHEMBL
Carbonic anhydrase Enzyme Ki 5.24 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.15 CHEMBL
Astrosclerin-3 Enzyme Ki 6.29 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 4.89 CHEMBL
Delta carbonic anhydrase Enzyme Ki 6.42 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.17 CHEMBL
Cytochrome c oxidase subunit 1 Enzyme IC50 4.02 CHEMBL
Carbonic anhydrase Enzyme Ki 6.79 CHEMBL
Carbonic anhydrase, alpha family Enzyme Ki 6.28 CHEMBL
Carbonate dehydratase Enzyme Ki 8.28 CHEMBL

External reference:

IDSource
4021284 VUID
N0000148721 NUI
D02709 KEGG_DRUG
4021284 VANDF
C0913246 UMLSCUI
CHEBI:63634 CHEBI
COX PDB_CHEM_ID
CHEMBL865 ChEMBL_ID
DB00580 DRUGBANK_ID
C406224 MESH_SUPPLEMENTAL_RECORD_UI
119607 PUBCHEM_CID
2894 IUPHAR_LIGAND_ID
7815 INN_ID
2919279Q3W UNII
278567 RXNORM
16210 MMSL
d04778 MMSL
009503 NDDF
385583007 SNOMEDCT_US
385584001 SNOMEDCT_US
2919279Q3W INXIGHT DRUGS

Pharmaceutical products:

None